J.W. Cole Advisors Inc. Has $3.39 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

J.W. Cole Advisors Inc. grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,882 shares of the biopharmaceutical company’s stock after acquiring an additional 2,638 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Gilead Sciences were worth $3,393,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. PCA Investment Advisory Services Inc. bought a new stake in Gilead Sciences during the 2nd quarter worth approximately $25,000. OFI Invest Asset Management bought a new position in shares of Gilead Sciences during the third quarter valued at about $26,000. Tompkins Financial Corp boosted its holdings in Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the last quarter. Fortitude Family Office LLC bought a new stake in Gilead Sciences in the 4th quarter worth about $29,000. Finally, Rakuten Securities Inc. purchased a new stake in Gilead Sciences in the 4th quarter valued at about $33,000. 83.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $0.60 during midday trading on Friday, reaching $66.76. 10,657,002 shares of the company traded hands, compared to its average volume of 5,923,117. Gilead Sciences, Inc. has a 12 month low of $65.90 and a 12 month high of $87.86. The firm has a market capitalization of $83.12 billion, a price-to-earnings ratio of 14.84, a price-to-earnings-growth ratio of 0.91 and a beta of 0.19. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The firm’s fifty day moving average price is $71.96 and its two-hundred day moving average price is $76.53.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same period last year, the company posted $1.67 EPS. The business’s revenue was down 3.7% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences, Inc. will post 6.55 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 4.61%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s payout ratio is presently 68.44%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. StockNews.com lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday. Cantor Fitzgerald decreased their target price on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. Barclays cut their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a report on Monday, February 12th. Royal Bank of Canada decreased their price objective on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a report on Wednesday, February 14th. Finally, Wells Fargo & Company dropped their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Hold” and a consensus price target of $84.71.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.